Страна: Сінгапур
мова: англійська
Джерело: HSA (Health Sciences Authority)
(Core) Etonogestrel
ORGANON SINGAPORE PTE. LTD.
G03AC08
68mg
IMPLANT
(Core) Etonogestrel 68mg
SUBCUTANEOUS
Prescription Only
N.V. ORGANON
ACTIVE
2012-01-20
IMPLANON NXT S-CCDS-MK8415-IPTX-032014 IMPLANT FOR SUBDERMAL USE 1. NAME OF THE MEDICINAL PRODUCT Implanon NXT, 68 mg implant for subdermal use 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Implanon NXT is a radiopaque, non-biodegradable, progestagen-only, flexible implant preloaded in a sterile, ready-for-use, disposable applicator. Each radiopaque implant contains 68 mg of etonogestrel; the release rate is approximately 60-70 µg/day in week 5-6 and has decreased to approximately 35-45 µg/day at the end of the first year, to approximately 30- 40 µg/day at the end of the second year and to approximately 25-30 µg/day at the end of the third year. The innovative applicator is designed to be operated with one hand and to help facilitate correct subdermal insertion of the implant. For a full list of excipients, see section 6.1 "List of excipients". 3 PHARMACEUTICAL FORM Implant for subdermal use Radiopaque, non-biodegradable, white to off-white, soft, flexible rod with a length of 4 cm and 2 mm in diameter. 4 CLINICAL PARTICULARS 4.1 Therapeutic indication Contraception. 4.2 Posology and method of administration Pregnancy should be excluded before insertion of Implanon NXT . Healthcare professionals (HCPs) are strongly recommended to participate in a training session to become familiar with the use of the Implanon NXT applicator and techniques for insertion and removal of the Implanon NXT implant and where appropriate, request supervision prior to inserting or removing the implant. Prior to inserting the implant, carefully read and follow the instructions for insertion and removal of the implant in section 4.2.3 “How to insert Implanon Прочитайте повний документ
IMPLANON NXT® S-CCDS-OG8415-IPTx-072023 Implant for subdermal use 1. NAME OF THE MEDICINAL PRODUCT Implanon NXT, 68 mg implant for subdermal use 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Implanon NXT is a radiopaque, non-biodegradable, progestagen-only, flexible implant preloaded in a sterile, ready-for-use, disposable applicator. Each radiopaque implant contains 68 mg of etonogestrel; the release rate is approximately 60-70 µg/day in week 5-6 and has decreased to approximately 35-45 µg/day at the end of the first year, to approximately 30-40 µg/day at the end of the second year and to approximately 25-30 µg/day at the end of the third year. The innovative applicator is designed to be operated with one hand and to help facilitate correct subdermal insertion of the implant. For a full list of excipients, see section 6.1 "List of excipients". 3 PHARMACEUTICAL FORM Implant for subdermal use Radiopaque, non-biodegradable, white to off-white, soft, flexible rod with a length of 4 cm and 2 mm in diameter. 4 CLINICAL PARTICULARS 4.1 Therapeutic indication Contraception. 4.2 Posology and method of administration Pregnancy should be excluded before insertion of Implanon NXT. Healthcare professionals (HCPs) are strongly recommended to participate in a training session to become familiar with the use of the Implanon NXT applicator and the techniques for insertion and removal of the Implanon NXT implant and, where appropriate, request supervision prior to inserting or removing the implant. Before inserting the implant, carefully read and follow the instructions for insertion and removal of the implant in section 4.2.3 “How to insert Implanon NXT” and section 4.2.4 “How to remove Implanon NXT”. Videos demonstrating insertion and removal of the implant are available online at www.implanonnxtvideos.com. Please contact Organon, Designated Point of Contact (DPOC) at dpoc.singapore@organon.com if you have any questions. If you are unsure of the necessary steps to safely insert and/or remove Implanon NXT, do not atte Прочитайте повний документ